mCRC-话题@MedSci

#mCRC#

39篇内容 | 3449人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1642755, encodeId=05411642e55cb, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=Front Oncol：转移性结直肠癌（mCRC）患者使用标准的一线治疗时，KRAS G12C突变与其他亚型对于治疗的应答以及预后的比较, objectType=article, longId=218078, objectId=d5152180e802, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5152180e802, replyNumber=0, likeNumber=112, createdTime=2022-06-08, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5152180e802, moduleTitle=Front Oncol：转移性结直肠癌（mCRC）患者使用标准的一线治疗时，KRAS G12C突变与其他亚型对于治疗的应答以及预后的比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5152180e802)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642764, encodeId=3a531642e64ce, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=J Clin Oncol：MSS和MGMT缺失转移性结直肠癌（mCRC）使用替莫唑胺以及联合低剂量伊匹木单抗和那武利尤单抗治疗的疗效, objectType=article, longId=300870, objectId=d1753008e0b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d1753008e0b3, replyNumber=0, likeNumber=118, createdTime=2022-07-10, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d1753008e0b3, moduleTitle=J Clin Oncol：MSS和MGMT缺失转移性结直肠癌（mCRC）使用替莫唑胺以及联合低剂量伊匹木单抗和那武利尤单抗治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d1753008e0b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642766, encodeId=3d0b1642e66da, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=Br J Cancer：转移性结直肠癌(mCRC)伴有腹膜转移(PM)患者进行细胞减瘤手术(CRS)和腹腔热灌注化疗(HIPEC)时BRAF、KRAS和MSI对其影响, objectType=article, longId=301463, objectId=dae03014634c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dae03014634c, replyNumber=0, likeNumber=170, createdTime=2022-06-02, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dae03014634c, moduleTitle=Br J Cancer：转移性结直肠癌(mCRC)伴有腹膜转移(PM)患者进行细胞减瘤手术(CRS)和腹腔热灌注化疗(HIPEC)时BRAF、KRAS和MSI对其影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dae03014634c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642757, encodeId=01111642e5771, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=Front Oncol：左侧RAS/BRAF野生型转移性结直肠癌(mCRC)患者一线抗表皮生长因子受体(EGFR)为基础治疗后后续维持治疗管理, objectType=article, longId=219570, objectId=1d282195e0e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d282195e0e7, replyNumber=0, likeNumber=122, createdTime=2021-12-17, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d282195e0e7, moduleTitle=Front Oncol：左侧RAS/BRAF野生型转移性结直肠癌(mCRC)患者一线抗表皮生长因子受体(EGFR)为基础治疗后后续维持治疗管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d282195e0e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642754, encodeId=8d891642e544a, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=ASCO GI 2021：帕博利珠单抗可显著改善MSI-H/dMMR mCRC患者的PFS（KEYNOTE-177研究）, objectType=article, longId=205930, objectId=92a920593034, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92a920593034, replyNumber=0, likeNumber=107, createdTime=2021-07-16, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92a920593034, moduleTitle=ASCO GI 2021：帕博利珠单抗可显著改善MSI-H/dMMR mCRC患者的PFS（KEYNOTE-177研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92a920593034)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642753, encodeId=ad851642e5351, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=Br J Cancer：错配修复不足的转移性结直肠癌dMMR mCRC患者的生存分析, objectType=article, longId=202147, objectId=30ba20214e5d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30ba20214e5d, replyNumber=0, likeNumber=95, createdTime=2021-04-24, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30ba20214e5d, moduleTitle=Br J Cancer：错配修复不足的转移性结直肠癌dMMR mCRC患者的生存分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30ba20214e5d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642752, encodeId=5a0c1642e52f0, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=PLK1抑制剂Onvasertib治疗KRAS突变的mCRC患者：肿瘤消退和临床获益, objectType=article, longId=186925, objectId=3f7618692587, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f7618692587, replyNumber=0, likeNumber=134, createdTime=2021-01-07, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f7618692587, moduleTitle=PLK1抑制剂Onvasertib治疗KRAS突变的mCRC患者：肿瘤消退和临床获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f7618692587)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642750, encodeId=632a1642e5023, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=【2019 ASCO】化疗难治性mCRC患者瑞戈非尼治疗新进展, objectType=article, longId=167648, objectId=f57f16e64875, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f57f16e64875, replyNumber=0, likeNumber=101, createdTime=2019-08-06, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f57f16e64875, moduleTitle=【2019 ASCO】化疗难治性mCRC患者瑞戈非尼治疗新进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f57f16e64875)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642751, encodeId=74531642e51da, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=BRAF、EGFR、MEK，三靶向无化疗方案或成为BRAF V600E突变型mCRC新标准治疗, objectType=article, longId=175233, objectId=c5631e5233ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5631e5233ba, replyNumber=0, likeNumber=164, createdTime=2019-11-10, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5631e5233ba, moduleTitle=BRAF、EGFR、MEK，三靶向无化疗方案或成为BRAF V600E突变型mCRC新标准治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5631e5233ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642747, encodeId=189c1642e47cd, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=J Clin Oncol:CheckMate 142研究：dMMR/MSI-H 型mCRC的联合免疫治疗时代, objectType=article, longId=127483, objectId=749e12e48327, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=749e12e48327, replyNumber=0, likeNumber=106, createdTime=2018-09-26, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=749e12e48327, moduleTitle=J Clin Oncol:CheckMate 142研究：dMMR/MSI-H 型mCRC的联合免疫治疗时代, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=749e12e48327)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642748, encodeId=c0721642e4823, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=JAMA Surg：mCRC的靶向治疗：肿瘤原发部位和死亡率是否相关？, objectType=article, longId=131399, objectId=622d13139946, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=622d13139946, replyNumber=0, likeNumber=121, createdTime=2018-11-16, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=622d13139946, moduleTitle=JAMA Surg：mCRC的靶向治疗：肿瘤原发部位和死亡率是否相关？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=622d13139946)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642749, encodeId=56611642e49d5, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=JCO：贝伐珠单抗治疗mCRC 18q11.2-q12.1缺失是福还是祸？, objectType=article, longId=146653, objectId=33e41466537f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33e41466537f, replyNumber=0, likeNumber=108, createdTime=2019-04-08, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33e41466537f, moduleTitle=JCO：贝伐珠单抗治疗mCRC 18q11.2-q12.1缺失是福还是祸？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33e41466537f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642742, encodeId=2cd11642e42bf, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=合理制定靶向药物使用顺序，使mCRC患者获益很大化, objectType=article, longId=106021, objectId=c9b710602185, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c9b710602185, replyNumber=0, likeNumber=89, createdTime=2017-12-10, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c9b710602185, moduleTitle=合理制定靶向药物使用顺序，使mCRC患者获益很大化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c9b710602185)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642744, encodeId=fb351642e445e, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=ANN ONCOL:液体活检RAS可指导mCRC一线抗EGFR治疗, objectType=article, longId=108461, objectId=a9e21084618a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9e21084618a, replyNumber=0, likeNumber=78, createdTime=2017-11-15, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9e21084618a, moduleTitle=ANN ONCOL:液体活检RAS可指导mCRC一线抗EGFR治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9e21084618a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642741, encodeId=cc511642e41da, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=Ann Oncol：血液和肿瘤组织的RAS突变检测方法用于指导mCRC抗EGFR治疗的一致性, objectType=article, longId=105800, objectId=603c10580098, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=603c10580098, replyNumber=0, likeNumber=98, createdTime=2017-08-18, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=603c10580098, moduleTitle=Ann Oncol：血液和肿瘤组织的RAS突变检测方法用于指导mCRC抗EGFR治疗的一致性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=603c10580098)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642746, encodeId=8dc21642e46e9, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=J Clin OncoL:BRAF突变mCRC再细分，新突变亚型引人瞩目, objectType=article, longId=108813, objectId=a8b410881330, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8b410881330, replyNumber=0, likeNumber=125, createdTime=2018-07-14, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8b410881330, moduleTitle=J Clin OncoL:BRAF突变mCRC再细分，新突变亚型引人瞩目, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8b410881330)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642745, encodeId=c73d1642e4505, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=ANNALS OF ONCOLOGY：液体活检RAS可指导mCRC一线抗EGFR治疗, objectType=article, longId=108462, objectId=42e5108462d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=42e5108462d0, replyNumber=0, likeNumber=97, createdTime=2018-04-15, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=42e5108462d0, moduleTitle=ANNALS OF ONCOLOGY：液体活检RAS可指导mCRC一线抗EGFR治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=42e5108462d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642743, encodeId=d3441642e435c, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=【ASCO 2017】欧美权威专家访谈集锦：Her-2扩增检测为mCRC末线治疗方案提供线索, objectType=article, longId=106341, objectId=64261063415a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64261063415a, replyNumber=0, likeNumber=107, createdTime=2018-06-19, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64261063415a, moduleTitle=【ASCO 2017】欧美权威专家访谈集锦：Her-2扩增检测为mCRC末线治疗方案提供线索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=64261063415a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642740, encodeId=60d21642e40da, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=Ann Oncol：血浆ctDNA RAS基因突变分析用于mCRC患者诊断和治疗监测效果佳, objectType=article, longId=105262, objectId=a60610526214, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a60610526214, replyNumber=0, likeNumber=111, createdTime=2018-03-14, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a60610526214, moduleTitle=Ann Oncol：血浆ctDNA RAS基因突变分析用于mCRC患者诊断和治疗监测效果佳, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a60610526214)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642738, encodeId=cc211642e3856, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=RECOURSE试验III期：TAS-102对比安慰剂治疗已给予更佳支持治疗且能耐受标准化疗的mCRC患者, objectType=article, longId=43695, objectId=811c4369574, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=811c4369574, replyNumber=0, likeNumber=112, createdTime=2015-04-18, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=811c4369574, moduleTitle=RECOURSE试验III期：TAS-102对比安慰剂治疗已给予更佳支持治疗且能耐受标准化疗的mCRC患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=811c4369574)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

mCRC

2020-05-29

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

Front Oncol：转移性结直肠癌（mCRC）患者使用标准的一线治疗时，KRAS G12C突变与其他亚型对于治疗的应答以及预后的比较

2022-06-08

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

J Clin Oncol：MSS和MGMT缺失转移性结直肠癌（mCRC）使用替莫唑胺以及联合低剂量伊匹木单抗和那武利尤单抗治疗的疗效

2022-07-10

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

Br J Cancer：转移性结直肠癌(mCRC)伴有腹膜转移(PM)患者进行细胞减瘤手术(CRS)和腹腔热灌注化疗(HIPEC)时BRAF、KRAS和MSI对其影响

2022-06-02

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

Front Oncol：左侧RAS/BRAF野生型转移性结直肠癌(mCRC)患者一线抗表皮生长因子受体(EGFR)为基础治疗后后续维持治疗管理

2021-12-17

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

ASCO GI 2021：帕博利珠单抗可显著改善MSI-H/dMMR mCRC患者的PFS（KEYNOTE-177研究）

2021-07-16

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

Br J Cancer：错配修复不足的转移性结直肠癌dMMR mCRC患者的生存分析

2021-04-24

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

PLK1抑制剂Onvasertib治疗KRAS突变的mCRC患者：肿瘤消退和临床获益

2021-01-07

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

【2019 ASCO】化疗难治性mCRC患者瑞戈非尼治疗新进展

2019-08-06

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

BRAF、EGFR、MEK，三靶向无化疗方案或成为BRAF V600E突变型mCRC新标准治疗

2019-11-10

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

J Clin Oncol:CheckMate 142研究：dMMR/MSI-H 型mCRC的联合免疫治疗时代

2018-09-26

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

JAMA Surg：mCRC的靶向治疗：肿瘤原发部位和死亡率是否相关？

2018-11-16

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

JCO：贝伐珠单抗治疗mCRC 18q11.2-q12.1缺失是福还是祸？

2019-04-08

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

合理制定靶向药物使用顺序，使mCRC患者获益很大化

2017-12-10

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

ANN ONCOL:液体活检RAS可指导mCRC一线抗EGFR治疗

2017-11-15

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

Ann Oncol：血液和肿瘤组织的RAS突变检测方法用于指导mCRC抗EGFR治疗的一致性

2017-08-18

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

J Clin OncoL:BRAF突变mCRC再细分，新突变亚型引人瞩目

2018-07-14

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

ANNALS OF ONCOLOGY：液体活检RAS可指导mCRC一线抗EGFR治疗

2018-04-15

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

【ASCO 2017】欧美权威专家访谈集锦：Her-2扩增检测为mCRC末线治疗方案提供线索

2018-06-19

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

Ann Oncol：血浆ctDNA RAS基因突变分析用于mCRC患者诊断和治疗监测效果佳

2018-03-14

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

RECOURSE试验III期：TAS-102对比安慰剂治疗已给予更佳支持治疗且能耐受标准化疗的mCRC患者

2015-04-18

科室
- - 订阅+
  - 更多科室
工具
服务